Navigation Links
BioMarin to Present at the Baird Growth Stock Conference
Date:5/7/2009

NOVATO, Calif., May 7 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Business and Corporate Development of BioMarin, will present a company update at the Baird Growth Stock Conference in Chicago on Thursday, May 14, 2009 at 10:40 a.m. CT.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase I clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

    Contacts:

    Investors                      Media
    Eugenia Shen                   Susan Berg
    BioMarin Pharmaceutical Inc.   BioMarin Pharmaceutical Inc.
    (415) 506-6570                 (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin Announces First Quarter 2009 Financial Results
2. BioMarin to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30 at 5:00 p.m. ET (23:00 CET)
3. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
4. BioMarin to Present at the 4th Annual Citi Biotech Day
5. BioMarins Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
6. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
7. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
8. BioMarin to Present at the Piper Jaffray Healthcare Conference
9. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
10. BioMarin to Present at the Credit Suisse Healthcare Conference
11. BioMarin Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , February 9, 2016 Three-Year ... Enables Children to Take Part in Life-Changing Camp ... new initiative designed to positively affect the lives of children born ... care. --> SHPG ) is announcing a new initiative ... diseases, as well as the future of rare disease care. ...
(Date:2/9/2016)... , Feb. 9, 2016 ... Inhibitors-Pipeline Insights, 2016", report provides in depth ... development activities around the Protein-Tyrosine Phosphatase 1B ... product profiles in various stages of development ... II, Phase III and Preregistration. Report covers ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016 Should ... standard bone cement products to prevent infection after standard ... that the experts at ECRI Institute have been fielding ... Infection or Fighting Your Bottom Line?" ... Your Bottom Line?" --> While ...
(Date:2/8/2016)... , February 8, 2016 ... Private Limited, an innovation-driven oncology company developing next ... less toxic, today announced that chairman emeritus of ... invested in the company as part of the ... joining existing investors Navam Capital and Aarin Capital. ...
Breaking Biology Technology:
(Date:2/2/2016)... --Technology Enhancements Accelerate Growth of X-ray Imaging This ... computed radiography markets in Thailand , ... (TIM). It provides an in-depth analysis of ... regional market drivers and restraints. The study offers revenue ... attractiveness, both for digital and computed radiography. Market participants ...
(Date:2/1/2016)... smart wallet ( www.wocketwallet.com ) announces the launch of a new video ... Las Vegas , where Joey appeared at the Wocket ... Vegas , where Joey appeared at the Wocket booth to meet ... filmed at the Consumer Electronics Show (CES2016) in Las Vegas ... greet fans. --> --> The ...
(Date:1/22/2016)... DUBLIN , January 22, 2016 ... has announced the addition of the  ... to their offering. --> ... of the  "Global Behavioral Biometric Market ... --> Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ...
Breaking Biology News(10 mins):